Search results (1)
« Back to NewsR21 malaria vaccine phase III trial confirms high efficacy and safety
5 February 2024
The phase III trial data results of the R21/Matrix-M vaccine, developed by the Jenner Institute and the Serum Institute of India have confirmed high efficacy and supported regulatory approvals and licensure in several African countries.